Beyond the Average Effect: Identifying the Trauma Patients Who Benefit Most from Tranexamic Acid
Thrombosis and Haemostasis · 01.10.2026 · 126 (10) · 1014-1016
DOI: 10.1055/a-2848-3364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.10.2026. Verfasst von Eva Soler-Espejo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), University of Murcia, Hospital Clínico Universitario Virg…. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
10.1055/s-00035024 Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits plasminogen activation and stabilizes fibrin clots by blocking fibrinolysis. Over the past decade, renewed interest in this antifibrinolytic agent has emerged following large randomized trials demonstrating survival benefits in major bleeding conditions such as trauma and postpartum hemorrhage. Additionally, it has shown benefit in reducing blood loss in several surgical scenarios, especially in cardiac and major orthopedic surgery.[ 1 ] [ 2 ] The CRASH-2 trial included more than 20,000 trauma patients with significant bleeding or risk of hemorrhage, showing that early administration of TXA reduced all-cause mortality without increasing thrombotic complications.[ 3 ] Similarly, the CRASH-3 trial evaluated TXA in patients with traumatic brain injury, demonstrating a reduction in head injury–related death in patients with mild-to-moderate injury, particularly when treatment was administered within 3 hours.[ 4 ] More recently, trials evaluating prehospital administration, such as PATCH-Trauma, have explored whether even earlier delivery of TXA may further improve outcomes in severely injured patients.[ 5 ] Despite these advances, the benefit of TXA is not uniform across trauma populations. Recent evidence suggests that the overall mortality reduction is modest and (perhaps unsurprisingly) varies substantially according to injury pattern and baseline risk.[ 6 ] This reflects the reality of real-world practice, where many patients exhibit clinical complexity phenotypes that are affected by demography and comorbidities, the latter tending to cluster together. The latter is not just in trauma populations but is evident in various acute and chronic disease states that are impacted by multimorbidity and polypharmacy, such as atrial fibrillation.[ 7 ] In this issue of the journal, Tachino et al[ 8 ] propose a more refined approach to TXA use in trauma patients. While randomized controlled trials (RCTs) have established the efficacy of TXA, identifying the patients who derive the greatest benefit remains a clinical challenge. To address this issue, the authors performed a two-phase analysis combining a systematic review of five RCTs with a machine learning–based phenotypic characterization of trauma patients using data from the Japan Trauma Data Bank. Across the RCTs, mortality in control groups ranged from 10 to 21.8%, whereas mortality across phenotype-defined subgroups varied markedly from 3.9 to 53.4%. Correspondingly, the estimated number needed to treat (NNT) ranged from 22 to 68 in the RCTs and from 10 to 98 in phenotype-based analyses. Importantly, an inverse relationship between baseline mortality and NNT was observed, indicating that TXA confers greater absolute benefit in higher-risk patients. This finding highlights the clinical relevance of treatment-effect heterogeneity, suggesting that average effects derived from conventional trials may obscure substantial benefits within specific patient subsets. The authors further show that trauma phenotypes, defined using routinely available clinical variables during initial assessment, can identify patients likely to benefit from TXA beyond traditional criteria based on anatomical injury patterns or hemodynamic thresholds. Four phenotypes[ 1 ] [ 2 ] [ 6 ] [ 8 ] were associated with improved survival following TXA administration, with phenotype 8—characterized by severe injury and hemodynamic instability—showing the greatest treatment effect (NNT = 10). These observations support the potential role of phenotype-based stratification as a pragmatic enrichment strategy to improve therapeutic targeting in trauma care. Trauma-induced coagulopathy reflects a complex interaction between tissue injury, inflammation, endothelial dysfunction, and fibrinolytic activation. Patients with greater physiological derangement are more prone to hyperfibrinolysis, providing a plausible biological rationale for differential TXA responsiveness across clinical phenotypes.[ 9 ] [ 10 ] [ 11 ] Linking observable clinical patterns with underlying hemostatic mechanisms may therefore represent an important step toward biologically informed treatment selection.[ 8 ] TXA is inexpensive, widely available, and has demonstrated a favorable safety profile in large trials, with no consistent increase in thrombotic complications.[ 12 ] It is recommended in Patient Blood Management programmes and recognized as an essential medicine by the World Health Organization.[ 13 ] Nevertheless, universal administration to all trauma patients may not represent the most efficient strategy. While an NNT of 10 indicates substantial clinical benefit, values approaching 100 suggest limited absolute impact. A more selective approach may optimize resource use while minimizing unnecessary exposure in patients with low expected benefit. Several limitations should be acknowledged. Phenotype-guided analyses are derived from observational registry data and remain subject to residual confounding. Furthermore, the phenotypes were developed within a single national trauma system, and their reproducibility in different healthcare settings requires confirmation. Prospective validation will be essential before phenotype-guided TXA administration can be implemented in routine clinical practice. Nevertheless, this work points toward an important shift in trauma research priorities. Rather than focusing solely on whether TXA should be administered, future investigations may need to determine how best to identify the patients most likely to benefit from antifibrinolytic therapy. The integration of rapid clinical phenotyping with emerging decision-support tools and biomarker-based strategies may facilitate more individualized hemostatic management. Heterogeneity in complexity phenotyping also highlights the need for holistic or integrated care management approaches, which have been associated with improved clinical outcomes, for example, in acute and chronic conditions such as atrial fibrillation.[ 14 ] [ 15 ] Ultimately, the study by Tachino et al underscores the need to move beyond uniform treatment paradigms in trauma care. As understanding of trauma-induced coagulopathy evolves, phenotype-guided approaches may enable a more precise and clinically meaningful application of antifibrinolytic therapy. In this context, the key question may no longer be whether TXA should be used in trauma, but how clinicians can better identify the patients most likely to benefit from it, while also enabling the design of risk-enriched clinical trials in which treatment effects can be more clearly detected. ([ Fig. 1 ]) Fig. 1 Phenotype-guided optimization of tranexamic acid use in trauma. Publication History Received: 01 April 2026 Accepted: 01 April 2026 Article published online: 23 April 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Autor:innen und Institutionen
- Department of Hematology, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), University of Murcia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Zitieren
APA
Soler-Espejo, E., & Roldán, V. (2026). Beyond the Average Effect: Identifying the Trauma Patients Who Benefit Most from Tranexamic Acid. Thrombosis and Haemostasis, 126(10), 1014-1016. https://doi.org/10.1055/a-2848-3364
Vancouver
Soler-Espejo E, Roldán V. Beyond the Average Effect: Identifying the Trauma Patients Who Benefit Most from Tranexamic Acid. Thrombosis and Haemostasis. 2026;126(10):1014-1016. doi:10.1055/a-2848-3364
BibTeX
@article{SolerEspejo2026,
author = {Soler-Espejo, Eva and Roldán, Vanessa},
title = {Beyond the Average Effect: Identifying the Trauma Patients Who Benefit Most from Tranexamic Acid},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {10},
pages = {1014--1016},
doi = {10.1055/a-2848-3364}
}
EUVIMED